Ameriprise
TARS icon

Ameriprise’s Tarsus Pharmaceuticals TARS Stock Holding History

Ameriprise’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$535K Sell
8,508
-43
-0.5% -$2.75K ﹤0.01% 3643
2026
Q1 		$600K Sell
8,551
-52
-0.6% -$3.63K ﹤0.01% 3516
2025
Q4 		$704K Sell
8,603
-40
-0.5% -$2.99K ﹤0.01% 3493
2025
Q3 		$514K Sell
8,643
-97
-1% -$4.78K ﹤0.01% 3613
2025
Q2 		$354K Sell
8,740
-50,174
-85% -$2.26M ﹤0.01% 3641
2025
Q1 		$3.03M Buy
58,914
+11,229
+24% +$555K ﹤0.01% 2665
2024
Q4 		$2.64M Buy
47,685
+8,336
+21% +$379K ﹤0.01% 2771
2024
Q3 		$1.29M Sell
39,349
-8,799
-18% -$247K ﹤0.01% 3108
2024
Q2 		$1.31M Sell
48,148
-10,219
-18% -$344K ﹤0.01% 3045
2024
Q1 		$2.12M Buy
58,367
+4,917
+9% +$145K ﹤0.01% 2840
2023
Q4 		$1.08M Buy
53,450
+145
+0.3% +$2.42K ﹤0.01% 3154
2023
Q3 		$947K Buy
53,305
+37,430
+236% +$662K ﹤0.01% 3168
2023
Q2 		$287K Buy
+15,875
New +$252K ﹤0.01% 3622

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameriprise's TARS Position: Q2 2026 in Review

Ameriprise reduced its Tarsus Pharmaceuticals (TARS) stake by 0.5% in Q2 2026, selling an estimated $2.75K and leaving 8,508 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #3643.

Ameriprise first reported a position in TARS in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.03M in Q1 2025. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Ameriprise held 8,508 shares of Tarsus Pharmaceuticals worth $535K as of Q2 2026.
  • Ameriprise sold 43 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.75K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3643 holding.
  • Ameriprise first reported a position in Tarsus Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Ameriprise's Tarsus Pharmaceuticals position peaked at $3.03M in Q1 2025.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.